Executive functioning and quality of life in acromegaly
- PMID: 30655710
- PMCID: PMC6322494
- DOI: 10.2147/PRBM.S183950
Executive functioning and quality of life in acromegaly
Abstract
Introduction: Active acromegaly is a rare chronic endocrine disorder caused by excessive growth hormone (GH). Clinical studies suggest that cognitive performance is impaired in acromegaly - particularly executive function as well as short- and long-term memory. This study compared the quality of life (QoL) and executive functioning in acromegaly patients vs healthy controls.
Materials and methods: This was an observational case-control study on 38 subjects divided into 19 acromegaly patients and 19 matched controls. The groups were evaluated for QoL, attention, and executive function. All subjects completed Acromegaly Quality of Life Questionnaire (AcroQoL), Trail Making Test (parts A and B), Stroop, and phonemic fluency tests.
Results: Acromegaly patients had an AcroQoL global score that was significantly lower than controls. There were significant differences between the acromegaly group and the control group in terms of the physical effects (P=0.001) and appearance (P<0.001) but not for personal relationships (P=0.421). Acromegaly patients performed worse in the trail making test part B. They provided significantly fewer words than healthy subjects in phonemic fluency testing. Although patients performed generally worse than controls, no significant differences were noted in the trail making test part A, Stroop test, and the constrained phonemic fluency.
Conclusion: Acromegaly patients display worse executive functioning than healthy controls and have a decreased QoL.
Keywords: acromegaly; cognition; executive function; growth hormone.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Similar articles
-
Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study.Eur J Endocrinol. 2006 Aug;155(2):269-77. doi: 10.1530/eje.1.02214. Eur J Endocrinol. 2006. PMID: 16868140
-
Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study.Clin Endocrinol (Oxf). 2017 Jun;86(6):806-815. doi: 10.1111/cen.13331. Epub 2017 Apr 18. Clin Endocrinol (Oxf). 2017. PMID: 28316090
-
Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire.J Clin Endocrinol Metab. 2005 Jun;90(6):3337-41. doi: 10.1210/jc.2004-1565. Epub 2005 Mar 8. J Clin Endocrinol Metab. 2005. PMID: 15755865
-
Quality of life in acromegaly.Neuroendocrinology. 2006;83(3-4):224-9. doi: 10.1159/000095532. Epub 2006 Oct 13. Neuroendocrinology. 2006. PMID: 17047387 Review.
-
Quality of Life in Acromegaly.Neuroendocrinology. 2016;103(1):106-11. doi: 10.1159/000375451. Epub 2015 Feb 5. Neuroendocrinology. 2016. PMID: 25661974 Review.
Cited by
-
Differences in quality of life between genders in acromegaly.Endocrinol Diabetes Metab. 2021 Feb 3;4(2):e00229. doi: 10.1002/edm2.229. eCollection 2021 Apr. Endocrinol Diabetes Metab. 2021. PMID: 33855226 Free PMC article.
-
Quality of life and psychological status in people with acromegaly in relation to facial changes.Endocr Connect. 2025 May 1;14(5):e240545. doi: 10.1530/EC-24-0545. Epub 2025 Apr 25. Endocr Connect. 2025. PMID: 40214517 Free PMC article.
-
The potential utility of the SAGIT instrument in the clinical assessment of patients with acromegaly, a large single-centre study.Sci Rep. 2023 Feb 25;13(1):3286. doi: 10.1038/s41598-023-29957-3. Sci Rep. 2023. PMID: 36841880 Free PMC article.
-
Cognitive Dysfunction, an Increasingly Valued Long-Term Impairment in Acromegaly.J Clin Med. 2023 Mar 15;12(6):2283. doi: 10.3390/jcm12062283. J Clin Med. 2023. PMID: 36983284 Free PMC article. Review.
-
Physical exercise improves functional capacity and quality of life in patients with acromegaly: a 12-week follow-up study.Endocrine. 2019 Nov;66(2):301-309. doi: 10.1007/s12020-019-02011-x. Epub 2019 Jul 17. Endocrine. 2019. PMID: 31317523
References
-
- Niculescu DA, Baciu IF, Capatina C, et al. Acromegaly treatment in Romania. How close are we to disease control? Endokrynol Pol. 2017;68(5):519–523. - PubMed
LinkOut - more resources
Full Text Sources